Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>Resources>Webcasts>This Webcast

Developing Dicer-Substrate siRNA Drugs

Mark Behlke, Chief Scientific Officer, Integrated DNA Technologies, speaking at RNAi World Congress 2009
Date Posted: Friday, October 16, 2009
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Discover the Latest NGS-Based Assays Guiding Precision Oncology
IDT joins forces with Foundation Medicine in AMP workshop.
Saturday, November 08, 2014
IDT Acquires SURVEYOR® Nuclease Business from Transgenomic
Addition of SURVEYOR enzyme and kits expands IDT's molecular biology product offerings.
Wednesday, July 02, 2014
Providing a Rapid and Reliable Method of Gene Cloning
Integrated DNA Technologies will be speaking at the upcoming Antibody Engineering and Therapeutics conference.
Monday, December 02, 2013
Webinar: the Cutting-edge qPCR Approach to Single-cell Expression Profiling
Join IDT and Professor Mikael Kubista for insight into pioneering qPCR methods, June 25.
Monday, June 24, 2013
IDT Launches Michael Zuker’s UNAFold Page
UNAFold secondary structure prediction software to be used to accurately detect secondary structures within sequences submitted by customers.
Thursday, December 02, 2010
IDT Presents at Presidential Commission for the Study of Bioethical Issues
Representing the International Gene Synthesis Consortium and its ongoing work to prevent the misuse of synthetic genes.
Tuesday, September 21, 2010
IDT is Awarded Further Funding for Gene Silencing Research
Company receives a Phase II SIBR grant to fund the ongoing ‘Gene Silencing with U1 Adapter Oligonucleotides’ research project.
Thursday, July 22, 2010
IDT Earns ISO 9001:2008 Certification at its European Oligonucleotide Production Headquarters
Worldwide certification of quality systems at all manufacturing operations completed.
Tuesday, April 27, 2010
Integrated DNA Technologies and Glycon Partner in Australia
Glycon will offer Australia’s scientists local sales and technical support of IDT’s products, complementing IDT’s existing global customer care network.
Monday, April 19, 2010
IDT Secures Funding for new Gene Silencing Research
IDT has been awarded $99,750 from NIH to continue work on its ‘Gene Silencing with U1 Adapter Oligonucleotides’ research project.
Monday, September 07, 2009
Major International Conferences to Hear About the Risks and Rewards of Synthetic Biology
IDT will be presenting recent developments in RNAi research, at Analytica and the RNAi World Congress.
Wednesday, March 19, 2008
IDT Acquires Belgian Manufacturer RNA-TEC
Purchase expands IDT's large-scale RNA synthesis capabilities; builds presence in European markets.
Tuesday, September 19, 2006
Scientific News
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos